AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue forecast of $31 billion for both drugs.
AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline
Where Today's News Shapes Tomorrow
